HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 9

Overview of DESTINY-Breast06

, , , ,

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
Now Viewing
EP. 9: Overview of DESTINY-Breast06
EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

  • Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
    • DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
      • Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
      • Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?